APIM THERAPEUTICS IS A BIOTECHNOLOGY COMPANY DEDICATED TO THE DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS TARGETING STRESS RESPONSES.

At APIM THERAPEUTICS AS we focus on the development and commercialization of novel combinatorial therapies in cancer cells. Our approach is based on targeting PCNA, a master “hub” protein regulating cell responses to stress e.g. upon DNA Damage Response triggered by  several anti-cancer agents (chemotherapy & targeted agents). Through development of first-in-class peptide drugs which contain a novel PCNA-interacting Peptide Motif termed APIM, the company offers a novel intervention point allowing cancer-specific tumor cell elimination. The company's lead drug, ATX-101, has entered the clinic in August 2018.

 

DRUG PIPELINE

Drug PipelineAPIM Therapeutics AS is developing a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. Our lead compound, ATX-101, has shown proof-of-concept in multiple preclinical in vitro and in vivo cancer models.

Learn More

 

ABOUT US

APIM Therapeutics AS is a venture capital supported spin off from the Norwegian University of Science and Technology (NTNU) at Trondheim, Norway.

Learn More

 

APIM THERAPEUTICS SNAPSHOT & NEWS

APIM Therapeutics SnapshotDownload this pdf for a short company summary.

ATX-101's clinical trial application was recently approved see press release.